Munich Reinsurance Co Stock Corp in Munich Acquires New Holdings in Humana Inc. $HUM

Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of Humana Inc. (NYSE:HUM) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 20,738 shares of the insurance provider’s stock, valued at approximately $5,395,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new stake in shares of Humana in the second quarter valued at approximately $32,000. Mather Group LLC. acquired a new position in shares of Humana during the third quarter worth approximately $34,000. AlphaCore Capital LLC bought a new position in Humana in the 2nd quarter worth approximately $39,000. Private Wealth Management Group LLC grew its holdings in Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after buying an additional 48 shares in the last quarter. Finally, SJS Investment Consulting Inc. increased its position in Humana by 19,300.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 193 shares during the period. Institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling

In other news, insider Sanjay K. Shetty acquired 810 shares of Humana stock in a transaction on Monday, February 23rd. The stock was bought at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the purchase, the insider owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.37% of the company’s stock.

Humana Trading Down 0.8%

Shares of NYSE:HUM opened at $179.27 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a market capitalization of $21.62 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.93 and a beta of 0.44. Humana Inc. has a 1-year low of $169.61 and a 1-year high of $315.35. The company has a 50 day moving average price of $221.75 and a 200 day moving average price of $252.27.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 2.0%. The ex-dividend date is Friday, March 27th. Humana’s payout ratio is presently 36.05%.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. Wolfe Research boosted their price target on Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. UBS Group reissued a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. Cantor Fitzgerald cut their price objective on shares of Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research note on Thursday, February 12th. Morgan Stanley set a $146.00 price objective on shares of Humana in a report on Thursday, February 12th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $344.00 target price on shares of Humana in a research report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $225.48.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.